account_balance
Investment manager · 13F filer · SEC CIK 1055951
Orbimed Advisors LLC
Reported value$5.28Bas of Jun 30, 2026
Positions121 35 new, 21 sold out
Top 10 weight43.0%EWTX alone is 12%
FiledAug 1445 days after quarter end
Portfolio · as of Jun 30, 2026
Where the money is
New or addedTrimmedHeld
EWTXEdgewise Therapeutics Inc
11.9%
ELVNEnliven Therapeutics Inc
6.5%Trimmed −15%
LLYEli Lilly & Co
5.9%Added +9%
MBXMBX Biosciences Inc
3.6%Trimmed −6%
Sinovac Biotech Ltd
3.5%
AZNAstrazeneca PLC
3.2%Added +37%
GPCRStructure Therapeutics Inc
2.2%Added +50%
SIONSionna Therapeutics Inc
2.1%Trimmed −28%
CRVSCorvus Pharmaceuticals Inc
2.0%
AVBPArrivent Biopharma Inc
2.0%
GHGuardant Health Inc
1.7%Added +34%
ARGXArgenx Se
1.6%Trimmed −32%
EWTXEdgewise Therapeutics Inc
11.9%
ELVN6.5%LLY5.9%MBX3.6%Sinovac Biotech Ltd3.5%
AZN3.2%GPCR2.2%SION2.1%CRVS2.0%AVBP2.0%GH1.7%ARGX1.6%Boxes show the top 12 stocks, sized against each other. The bar above shows how much of the fund they are. 13F only covers US-listed stocks, so foreign holdings and short positions are missing.
Show the top 12 as a list
EWTX Edgewise Therapeutics Inc 11.9% HeldELVN Enliven Therapeutics Inc 6.5% Trimmed −15%LLY Eli Lilly & Co 5.9% Added +9%MBX MBX Biosciences Inc 3.6% Trimmed −6%
Sinovac Biotech Ltd 3.5% Held
AZN Astrazeneca PLC 3.2% Added +37%GPCR Structure Therapeutics Inc 2.2% Added +50%SION Sionna Therapeutics Inc 2.1% Trimmed −28%CRVS Corvus Pharmaceuticals Inc 2.0% HeldAVBP Arrivent Biopharma Inc 2.0% HeldGH Guardant Health Inc 1.7% Added +34%ARGX Argenx Se 1.6% Trimmed −32%What changed